Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189403 | 0.87 | TSHR (0.61) | TSHREPHX2LMNAMAPK1NLRP1 | |
| SCHEMBL4200007 | 0.86 | TSHR (0.60) | TSHREPHX2LMNAMAPK1NLRP1 | |
| SCHEMBL5210719 | 0.85 | CYP1A2 (0.66) | TSHRLMNAMAPK1ROCK2ANO1 | |
| SCHEMBL4194897 | 0.83 | LMNA (0.56) | TSHREPHX2LMNAMAPK1NLRP1 | |
| SCHEMBL5213178 | 0.82 | CYP1A2 (0.64) | TSHRLMNAMAPK1ANO1CYP1A2 | |
| SCHEMBL4185414 | 0.82 | LMNA (0.58) | TSHREPHX2LMNAMAPK1NLRP1 | |
| SCHEMBL5214984 | 0.80 | CYP1A2 (0.50) | TSHRLMNAROCK2ANO1CYP1A2 | |
| SCHEMBL5645070 | 0.79 | LMNA (0.64) | TSHREPHX2LMNAMAPK1NLRP1 | |
| SCHEMBL5214954 | 0.79 | NPC1 (0.63) | TSHRLMNAMAPK1ROCK2ANO1 | |
| SCHEMBL4178412 | 0.79 | TSHR (0.52) | TSHREPHX2LMNAMAPK1NLRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | claimed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | claimed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | claimed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TSHR 3857/4885EPHX2 1046/4885LMNA 4372/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | TSHR 3059/4885EPHX2 480/4885LMNA 1690/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | TSHR 3181/4885EPHX2 523/4885LMNA 1594/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TSHR 4247/4885EPHX2 810/4885LMNA 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.